Pfizer Inc. $PFE Stock Purchased by Convergence Financial LLC

Convergence Financial LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 229.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 36,534 shares of the biopharmaceutical company’s stock after buying an additional 25,448 shares during the quarter. Convergence Financial LLC’s holdings in Pfizer were worth $1,042,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Retirement Wealth Solutions LLC boosted its holdings in Pfizer by 144.6% during the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 509 shares during the period. Evolution Wealth Management Inc. grew its position in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the last quarter. Keb Asset Management LLC bought a new position in Pfizer in the 2nd quarter valued at $26,000. Field & Main Bank purchased a new stake in Pfizer in the second quarter worth $27,000. Finally, Global Trust Asset Management LLC increased its stake in Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 1.1%

Shares of NYSE PFE opened at $29.46 on Thursday. Pfizer Inc. has a 52-week low of $23.62 and a 52-week high of $30.44. The firm has a market capitalization of $167.90 billion, a price-to-earnings ratio of 38.76, a PEG ratio of 2.04 and a beta of 0.32. The stock has a 50 day moving average price of $28.46 and a 200 day moving average price of $26.74. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. Pfizer’s dividend payout ratio is presently 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: ELREXFIO delivered a Phase 3 win. Pfizer said the MagnetisMM-32 trial met its primary endpoint, showing a statistically significant and clinically meaningful progression-free-survival benefit in relapsed or refractory multiple myeloma. The result could support broader use of the drug and strengthen Pfizer’s oncology pipeline. Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint
• Positive Sentiment: The FDA expanded the approval of TALZENNA plus XTANDI for earlier-line treatment of metastatic prostate cancer in patients with HRR gene mutations. The broader indication may increase the products’ commercial opportunity and diversify revenue beyond COVID products. FDA expands Pfizer’s Talzenna plus Xtandi approval
• Positive Sentiment: Analyst sentiment remained supportive. Scotiabank and Jefferies issued Buy ratings, while previews suggested Pfizer could beat upcoming earnings expectations. Pfizer’s recent results also exceeded consensus estimates for both revenue and adjusted earnings. Pfizer gets a Buy from Scotiabank
• Neutral Sentiment: Investors are focused on the upcoming Q3 report. Strong sales from newer medicines and a relatively attractive valuation could help, but the earnings release will need to demonstrate that Pfizer can offset ongoing COVID-product declines and longer-term patent risks. Pfizer Stock Ahead of Q3 Earnings
• Negative Sentiment: ELREXFIO’s benefit came with safety concerns. Reports highlighted higher infection rates, while median progression-free survival had not yet been reached. These details may temper the market’s reaction to the otherwise positive trial results. Pfizer’s ELREXFIO meets Phase 3 endpoint
• Negative Sentiment: Valuation and business-transition risks remain. Pfizer’s COVID revenue is declining, major products face future patent expirations, and one valuation analysis placed fair value near the current trading range, limiting perceived upside.

Analysts Set New Price Targets

Several analysts have recently weighed in on PFE shares. BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Scotiabank upped their price target on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. Finally, HSBC lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.72.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.